生物制品跨境分段生产风险分析与对策思考OA
Risk Analysis and Countermeasures for Cross-Border Segmented Production of Biological Products
生物制品生产具有供应链长、产品工艺复杂等特征,在全球化背景下,生物制品原液和制剂的跨境分段生产已成为提高产品可及性和优化资源配置的重要模式.为推动生物医药产业高质量发展,2024年国家药品监督管理局启动了生物制品分段生产试点工作,2026年新修订的《中华人民共和国药品管理法实施条例》进一步从制度层面明确有条件放开药品委托分段生产.在此背景下,生物制品生产从传统单一场地向多场地分段生产转变,这对质量管理体系和药品监管体系提出了新的挑战.本文分析了生物制品跨境分段生产的质量风险与监管挑战,基于 ICH《Q9(R1):质量风险管理》框架,从基础风险、技术风险、药品上市许可持有人(MAH)履责风险和监管风险4个维度构建风险评估框架,并提出针对性的风险防控措施.同时,从强化 MAH 主体责任和药品监管部门监管责任两个方面提出相应的政策思考,助力生物制品分段生产的有序实施.
The production of biological products features extended supply chains and complex manufacturing processes.In the context of globalization,cross-border segmented production of bulk drug substances and finished drug products has emerged as an important model to enhance product accessibility and optimize resource allocation.To promote the high-quality development of the biopharmaceutical industry,the National Medical Products Administration(NMPA)launched a pilot program for segmented production of biological products in 2024,and the newly revised Regulations for the Implementation of the Drug Administration Law of the People's Republic of China in 2026 further clarified the conditional liberalization of drug segmented production at the institutional level.Against this background,the production of biological products has shifted from a traditional single-site model to a multi-site segmented production,posing new challenges to both the quality management system and the drug regulatory system.This study analyzes the quality risks and regulatory challenges of cross-border segmented production of biological products.Based on the ICH Q9(R1)quality risk management framework,a risk assessment framework was developed spanning four dimensions:fundamental risks,technical risks,marketing authorization holder(MAH)responsibility risks,and regulatory risks.Targeted risk prevention and control measures are proposed accordingly.Furthermore,corresponding policy recommendations are put forward from two aspects:strengthening the primary responsibility of MAHs and enhancing the regulatory responsibility of drug regulatory authorities,so as to facilitate the orderly implementation of segmented production of biological products.
连家阁;朱梦雅;陈怡;黄淼;贾曈;谢金平;邵蓉
中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院
医药卫生
生物制品分段生产质量风险管理监管策略药品上市许可持有人
biological productssegmented productionquality risk managementregulatory strategymarketing authorization holder
《中国食品药品监管》 2026 (8)
50-57,8
评论